What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Participants will have a kidney biopsy followed approximately12 weeks later with a rilparencel injection into the biopsied kidney, then, approximately 12 weeks later a rilparencel injection into their contralateral kidney.”In the company’s words, NCT05099770 on ClinicalTrials.gov
- Tested for
- Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Main trialPhase 3
- “The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.”In the company’s words, NCT05099770 on ClinicalTrials.gov
- Other names
- Renal Autologous Cell Therapy
Other drugs for Type 2 Diabetes Mellitus
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up1
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2029 | Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | |
| Phase 3Withdrawn | 3 Sep 2024 | A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease | |
| Phase 2Completed | 17 Nov 2022 | A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease | |
| Phase 2Completed | Dec 2023 | A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease | |
| Phase 2Completed | 20 May 2025 | Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007) | |
| Phase 1Completed | 31 Jan 2023 | A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). | |
| Phase 1Terminated | 19 Mar 2024 | A Study of Participants With Chronic Kidney Disease Previously Treated With REACT |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026